Bausch + Lomb (BLCO) Competitors $13.83 +0.07 (+0.51%) Closing price 03:56 PM EasternExtended Trading$13.67 -0.16 (-1.16%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLCO vs. SNN, SOLV, PEN, STVN, GKOS, IRTC, NARI, TMDX, SLNO, and INSPShould you be buying Bausch + Lomb stock or one of its competitors? The main competitors of Bausch + Lomb include Smith & Nephew SNATS (SNN), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), iRhythm Technologies (IRTC), Inari Medical (NARI), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), and Inspire Medical Systems (INSP). These companies are all part of the "medical equipment" industry. Bausch + Lomb vs. Its Competitors Smith & Nephew SNATS Solventum Penumbra Stevanato Group Glaukos iRhythm Technologies Inari Medical TransMedics Group Soleno Therapeutics Inspire Medical Systems Smith & Nephew SNATS (NYSE:SNN) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment. Does the media favor SNN or BLCO? In the previous week, Bausch + Lomb had 10 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 11 mentions for Bausch + Lomb and 1 mentions for Smith & Nephew SNATS. Smith & Nephew SNATS's average media sentiment score of 1.43 beat Bausch + Lomb's score of 0.35 indicating that Smith & Nephew SNATS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bausch + Lomb 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of SNN or BLCO? 25.6% of Smith & Nephew SNATS shares are held by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by company insiders. Comparatively, 0.8% of Bausch + Lomb shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, SNN or BLCO? Smith & Nephew SNATS has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Do analysts prefer SNN or BLCO? Smith & Nephew SNATS presently has a consensus price target of $28.00, suggesting a potential downside of 7.47%. Bausch + Lomb has a consensus price target of $15.54, suggesting a potential upside of 12.38%. Given Bausch + Lomb's stronger consensus rating and higher possible upside, analysts clearly believe Bausch + Lomb is more favorable than Smith & Nephew SNATS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Smith & Nephew SNATS 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Bausch + Lomb 1 Sell rating(s) 8 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.23 Which has better valuation & earnings, SNN or BLCO? Smith & Nephew SNATS has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Smith & Nephew SNATS, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSmith & Nephew SNATS$5.81B2.28$412M$2.1614.01Bausch + Lomb$4.83B1.01-$317M-$1.03-13.43 Is SNN or BLCO more profitable? Smith & Nephew SNATS has a net margin of 0.00% compared to Bausch + Lomb's net margin of -7.50%. Bausch + Lomb's return on equity of 2.62% beat Smith & Nephew SNATS's return on equity.Company Net Margins Return on Equity Return on Assets Smith & Nephew SNATSN/A N/A N/A Bausch + Lomb -7.50%2.62%1.28% SummarySmith & Nephew SNATS beats Bausch + Lomb on 10 of the 16 factors compared between the two stocks. Get Bausch + Lomb News Delivered to You Automatically Sign up to receive the latest news and ratings for BLCO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BLCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLCO vs. The Competition Export to ExcelMetricBausch + LombMedical Services IndustryMedical SectorNYSE ExchangeMarket Cap$4.87B$7.29B$5.54B$20.55BDividend YieldN/A2.78%5.38%3.75%P/E Ratio-13.4327.9427.4028.05Price / Sales1.0132.39419.4646.08Price / Cash7.3522.0836.6322.31Price / Book0.746.698.084.59Net Income-$317M$233.06M$3.16B$985.44M7 Day Performance14.60%2.20%2.12%2.91%1 Month Performance20.21%4.93%4.43%5.47%1 Year Performance-5.66%35.84%35.62%14.61% Bausch + Lomb Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLCOBausch + Lomb3.3959 of 5 stars$13.83+0.5%$15.54+12.4%-6.2%$4.87B$4.83B-13.4313,500SNNSmith & Nephew SNATS3.7948 of 5 stars$29.17+1.2%$28.00-4.0%+22.2%$12.77B$5.81B13.5017,349Positive NewsSOLVSolventum0.9585 of 5 stars$73.21-0.5%$80.29+9.7%+51.6%$12.67B$8.31B33.8922,000Positive NewsAnalyst UpgradePENPenumbra4.7389 of 5 stars$254.41-1.0%$302.40+18.9%+41.8%$9.85B$1.19B240.014,500Positive NewsInsider TradeSTVNStevanato Group1.0554 of 5 stars€23.62+1.4%N/A+36.2%€7.15B€1.19B46.315,521Positive NewsAnalyst ForecastGap DownGKOSGlaukos4.4477 of 5 stars$96.80-3.3%$134.67+39.1%-12.8%$5.53B$383.48M-40.84780IRTCiRhythm Technologies1.2147 of 5 stars$150.95+3.6%$138.60-8.2%+44.8%$4.82B$591.84M-48.072,000Insider TradeNARIInari Medical0.5358 of 5 stars$79.97flat$69.22-13.4%N/A$4.68B$493.63M-59.24800TMDXTransMedics Group1.6051 of 5 stars$127.53+3.2%$127.33-0.2%-14.3%$4.31B$441.54M93.77210Positive NewsSLNOSoleno Therapeutics4.2136 of 5 stars$81.42+1.8%$107.10+31.5%+117.0%$4.10BN/A-17.6230Insider TradeINSPInspire Medical Systems4.8552 of 5 stars$129.88-0.8%$211.91+63.2%-2.7%$3.83B$840.11M59.851,246Positive News Related Companies and Tools Related Companies Smith & Nephew SNATS Competitors Solventum Competitors Penumbra Competitors Stevanato Group Competitors Glaukos Competitors iRhythm Technologies Competitors Inari Medical Competitors TransMedics Group Competitors Soleno Therapeutics Competitors Inspire Medical Systems Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BLCO) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bausch + Lomb Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Bausch + Lomb With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BLCO Stock Alerts